Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors

2005 ◽  
Vol 7 (7) ◽  
pp. 918-925 ◽  
Author(s):  
Michael D. Moore ◽  
Michael J. McGarvey ◽  
Rebecca A. Russell ◽  
Bryan R. Cullen ◽  
Myra O. McClure
2005 ◽  
Vol 112 (1-2) ◽  
pp. 100-107 ◽  
Author(s):  
Kai-Lang Wu ◽  
Xue Zhang ◽  
Jianlin Zhang ◽  
Yongbo Yang ◽  
Yong-Xin Mu ◽  
...  

2005 ◽  
Vol 79 (22) ◽  
pp. 14392-14403 ◽  
Author(s):  
Yong Guo ◽  
Hongyan Guo ◽  
Liang Zhang ◽  
Hongying Xie ◽  
Xin Zhao ◽  
...  

ABSTRACT Hepatitis B virus (HBV) causes acute and chronic hepatitis and hepatocellular carcinoma. Small interfering RNA (siRNA) and lamivudine have been shown to have anti-HBV effects through different mechanisms. However, assessment of the genome-wide effects of siRNA and lamivudine on HBV-producing cell lines has not been reported, which may provide a clue to interrogate the HBV-cell interaction and to evaluate the siRNA's side effect as a potential drug. In the present study, we designed seven siRNAs based on the conserved HBV sequences and tested their effects on the expression of HBV genes following sorting of siRNA-positive cells. Among these seven siRNAs, siRNA-1 and siRNA-7 were found to effectively suppress HBV gene expression. We further addressed the global gene expression changes in stable HBV-producing cells induced by siRNA-1 and siRNA-7 by use of human genome-wide oligonucleotide microarrays. Data from the gene expression profiling indicated that siRNA-1 and siRNA-7 altered the expression of 54 and 499 genes, respectively, in HepG2.2.15 cells, which revealed that different siRNAs had various patterns of gene expression profiles and suggested a complicated influence of siRNAs on host cells. We further observed that 18 of these genes were suppressed by both siRNA-1 and siRNA-7. Interestingly, seven of these genes were originally activated by HBV, which suggested that these seven genes might be involved in the HBV-host cell interaction. Finally, we have compared the effects of siRNA and lamivudine on HBV and host cells, which revealed that siRNA is more effective at inhibiting HBV expression at the mRNA and protein level in vitro, and the gene expression profile of HepG2.2.15 cells treated by lamivudine is totally different from that seen with siRNA.


2003 ◽  
Vol 8 (5) ◽  
pp. 769-776 ◽  
Author(s):  
Hilla Giladi ◽  
Mali Ketzinel-Gilad ◽  
Ludmila Rivkin ◽  
Yaakov Felig ◽  
Ofer Nussbaum ◽  
...  

2006 ◽  
Vol 131 (1) ◽  
pp. 10-15 ◽  
Author(s):  
I.A. Mechtcheriakova ◽  
M.A. Eldarov ◽  
L. Nicholson ◽  
M. Shanks ◽  
K.G. Skryabin ◽  
...  

Viruses ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 1189
Author(s):  
Kenneth Lundstrom

RNA interference (RNAi) represents a novel approach for alternative antiviral therapy. However, issues related to RNA delivery and stability have presented serious obstacles for obtaining good therapeutic efficacy. Viral vectors are capable of efficient delivery of RNAi as short interfering RNA (siRNA), short hairpin RNA (shRNA) and micro-RNA (miRNA). Efficacy in gene silencing for therapeutic applications against viral diseases has been demonstrated in various animal models. Rotavirus (RV) miR-7 can inhibit rotavirus replication by targeting the RV nonstructural protein 5. Viral gene silencing by targeting the RNAi pathway showed efficient suppression of hepatitis B virus replication by adeno-associated virus (AAV)-based delivery of RNAi hepatitis B virus (HBV) cassettes. Hepatitis C virus replication has been targeted by short hairpin RNA molecules expressed from lentivirus vectors. Potentially, RNAi-based approaches could be suitable for antiviral drugs against COVID-19.


Sign in / Sign up

Export Citation Format

Share Document